Next Article in Journal
Bioactive Compounds from Mexican Varieties of the Common Bean (Phaseolus vulgaris): Implications for Health
Next Article in Special Issue
Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity
Previous Article in Journal
Biochemical and Comparative Transcriptomic Analyses Identify Candidate Genes Related to Variegation Formation in Paeonia rockii
Previous Article in Special Issue
Novel Methylselenoesters as Antiproliferative Agents
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessArticle
Molecules 2017, 22(8), 1361;

Anticancer Activity of Ramalin, a Secondary Metabolite from the Antarctic Lichen Ramalina terebrata, against Colorectal Cancer Cells

Division of Polar Life Sciences, Korea Polar Research Institute, Incheon 21990, Korea
Department of Polar Life Science, University of Science and Technology, Incheon 21990, Korea
Department of Pharmacy, Graduate School, Sungkyunkwan University, Suwon 16419, Korea
Department of Pharmacological Medical and Agronomical Biotechnology, University of Science and Technology of Hanoi, Hanoi 100000, Vietnam
Author to whom correspondence should be addressed.
Received: 3 August 2017 / Revised: 11 August 2017 / Accepted: 15 August 2017 / Published: 17 August 2017
Full-Text   |   PDF [6744 KB, uploaded 17 August 2017]   |  


Colorectal cancer is a leading cause of death worldwide and occurs through the highly complex coordination of multiple cellular pathways, resulting in carcinogenesis. Recent studies have increasingly revealed that constituents of lichen extracts exhibit potent pharmaceutical activities, including anticancer activity against various cancer cells, making them promising candidates for new anticancer therapeutic drugs. The main objective of this study was to evaluate the anticancer capacities of ramalin, a secondary metabolite from the Antarctic lichen Ramalina terebrata, in the human colorectal cancer cell line HCT116. In this study, ramalin displayed concentration-dependent anticancer activity against HCT116 cells, significantly suppressing proliferation and inducing apoptosis. Furthermore, ramalin induced cell cycle arrest in the gap 2/mitosis (G2/M) phase through the modulation of hallmark genes involved in the G2/M phase transition, such as tumour protein p53 (TP53), cyclin-dependent kinase inhibitor 1A (CDKN1A), cyclin-dependent kinase 1 (CDK1) and cyclin B1 (CCNB1). At both the transcriptional and translational level, ramalin caused a gradual increase in the expression of TP53 and its downstream gene CDKN1A, while decreasing the expression of CDK1 and CCNB1 in a concentration-dependent manner. In addition, ramalin significantly inhibited the migration and invasion of colorectal cancer cells in a concentration-dependent manner. Taken together, these data suggest that ramalin may be a therapeutic candidate for the targeted therapy of colorectal cancer. View Full-Text
Keywords: colorectal cancer; ramalin; Antarctic lichen; cell cycle arrest; HCT116 colorectal cancer; ramalin; Antarctic lichen; cell cycle arrest; HCT116

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Suh, S.-S.; Kim, T.K.; Kim, J.E.; Hong, J.-M.; Nguyen, T.T.T.; Han, S.J.; Youn, U.J.; Yim, J.H.; Kim, I.-C. Anticancer Activity of Ramalin, a Secondary Metabolite from the Antarctic Lichen Ramalina terebrata, against Colorectal Cancer Cells. Molecules 2017, 22, 1361.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top